Lp(a)-Lowering Agents in Development: A New Era in Tackling the Burden of Cardiovascular Risk?
Lipoprotein (a) [Lp(a)] has been recognized as an independent, inherited, causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, thus representing a major target of residual CV risk. Currently, no drug has been officially approved for lowering Lp(a) levels,...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
MDPI AG
2025-05-01
|
| Colección: | Pharmaceuticals |
| Materias: | |
| Acceso en línea: | https://www.mdpi.com/1424-8247/18/5/753 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|